Skip to main content
CGEM
NASDAQ Life Sciences

Cullinan Reports $356M Cash, Runway Into 2029; Key Data Readouts Ahead

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$17.36
Mkt Cap
$1.082B
52W Low
$5.68
52W High
$19.43
52W Position info
206% above low
Off High info
11% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

CGEM has more than doubled off its 52-week low of $5.68.

Summary

Cullinan's Q2 update extends cash runway into 2029 with $356M on hand, easing near-term financing concerns. The company laid out a dense catalyst calendar: CLN-978 multi-dose RA data in Q3 2026, SLE data in Q4 2026, and Phase 2 starts in early 2027. Velinotamig SLE data also due Q4 2026, with a Phase 1/2 basket study in autoimmune cytopenias starting early 2027. In oncology, a potentially registrational Phase 2 for CLN-049 in AML begins this quarter following a positive FDA meeting. This follows positive Phase 1 data across the pipeline in recent months, and the cash position removes a key overhang.

At the time of this announcement, CGEM was trading at $17.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $5.68 to $19.43. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

CGEM - Latest Insights

CGEM
Oct 19, 2026, 7:00 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $13.35
Real-time Price: $11.51 info
Change: -$1.84 (-14%) info
Market Cap: $727.852M info
CGEM
Oct 01, 2026, 7:35 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $14.55
Real-time Price: $11.51 info
Change: -$3.04 (-21%) info
Market Cap: $727.852M info
CGEM
Sep 24, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $16.88
Real-time Price: $11.51 info
Change: -$5.37 (-32%) info
Market Cap: $727.852M info
CGEM
Sep 14, 2026, 7:29 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $20.60
Real-time Price: $11.51 info
Change: -$9.09 (-44%) info
Market Cap: $727.852M info
CGEM
Sep 13, 2026, 7:15 PM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $21.11
Real-time Price: $11.51 info
Change: -$9.60 (-45%) info
Market Cap: $727.852M info